Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Shin‐Ichi Fuchida"'
Autor:
Yutaka Shimazu, Junya Kanda, Satoru Kosugi, Tomoki Ito, Hitomi Kaneko, Kazunori Imada, Yuji Shimura, Shin-ichi Fuchida, Kentaro Fukushima, Hirokazu Tanaka, Satoshi Yoshihara, Kensuke Ohta, Nobuhiko Uoshima, Hideo Yagi, Hirohiko Shibayama, Ryosuke Yamamura, Yasuhiro Tanaka, Hitoji Uchiyama, Yoshiyuki Onda, Yoko Adachi, Hitoshi Hanamoto, Ryoichi Takahashi, Mitsuhiro Matsuda, Takashi Miyoshi, Teruhito Takakuwa, Masayuki Hino, Naoki Hosen, Shosaku Nomura, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori-Kondo, Junya Kuroda
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing
Externí odkaz:
https://doaj.org/article/f9f360c7a7b8496ea74ce32ada6c5c4d
Autor:
Hiroyuki Takamatsu, Tomohiro Matsuda, Shohei Mizuno, Tsutomu Takahashi, Shin-ichi Fuchida, Ichiro Hanamura, Keisuke Kataoka, Nobuhiro Tsukada, Morio Matsumoto, Akira Hangaishi, Noriko Doki, Naoyuki Uchida, Masashi Sawa, Yumiko Maruyama, Shingo Kurahashi, Koji Nagafuji, Yoriko Harazaki, Shinichi Kako, Shinsuke Iida, Tatsuo Ichinohe, Yoshinobu Kanda, Yoshiko Atsuta, Kazutaka Sunami, Multiple Myeloma Working Group in the Japanese Society for Transplantation and Cellular Therapy
Publikováno v:
Haematologica, Vol 108, Iss 12 (2023)
The incidence of second primary malignancies (SPM) in long-term survivors of multiple myeloma (MM) is increasing because of increased life expectancy. We retrospectively analyzed the risk factors for SPM in patients with MM after autologous stem cell
Externí odkaz:
https://doaj.org/article/4c8e66092f1f49feb08e8673e19eb376
Autor:
Aya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, Ryosuke Yamamura, Satoshi Yoshioka, Kazunori Imada, Yuji Shimura, Masaaki Hotta, Toshimitsu Matsui, Satoru Kosugi, Hitoshi Hanamoto, Hitoji Uchiyama, Satoshi Yoshihara, Shin-ichi Fuchida, Yoshiyuki Onda, Yasuhiro Tanaka, Kensuke Ohta, Mitsuhiro Matsuda, Junya Kanda, Adachi Yoko, Miki Kiyota, Eri Kawata, Ryoichi Takahashi, Kentaro Fukushima, Hirokazu Tanaka, Hideo Yagi, Teruhito Takakuwa, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Masayuki Hino
Publikováno v:
Leukemia Research Reports, Vol 20, Iss , Pp 100395- (2023)
To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnos
Externí odkaz:
https://doaj.org/article/82b016d7b6d64623a8db970348a6c492
Autor:
Aya Nakaya, Hirohiko Shibayama, Eiji Nakatani, Yuji Shimura, Satoru Kosugi, Hirokazu Tanaka, Shin‐Ichi Fuchida, Junya Kanda, Nobuhiko Uoshima, Hitomi Kaneko, Kazunori Imada, Kensuke Ohta, Tomoki Ito, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Chihiro Shimazaki, Akifumi Takaori‐Kondo, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 765-773 (2021)
Abstract A total of 129 symptomatic patients with multiple myeloma (MM) who underwent high‐dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) were analyzed. The 4‐year overall survival (OS) of patients with maintenance (n = 82
Externí odkaz:
https://doaj.org/article/fca8d9086da64417a2e3ae2412495e6f
Autor:
Yutaka Shimazu, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Ryosuke Yamamura, Satoru Kosugi, Yuji Shimura, Tomoki Ito, Shin-ichi Fuchida, Hitoji Uchiyama, Kentaro Fukushima, Satoshi Yoshihara, Hitoshi Hanamoto, Hirokazu Tanaka, Nobuhiko Uoshima, Kensuke Ohta, Hideo Yagi, Hirohiko Shibayama, Yoshiyuki Onda, Yasuhiro Tanaka, Yoko Adachi, Mitsuhiro Matsuda, Masato Iida, Takashi Miyoshi, Toshimitsu Matsui, Ryoichi Takahashi, Teruhito Takakuwa, Masayuki Hino, Naoki Hosen, Shosaku Nomura, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori-Kondo, Junya Kuroda
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: Daratumumab is one of the most widely used treatments for relapsed/refractory multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic response with daratumumab. Objectives: We hypothesized that a durable re
Externí odkaz:
https://doaj.org/article/de0e47159d65497ba083e4d809b5a35a
Autor:
Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Yuji Shimura, Shin-ichi Fuchida, Aya Nakaya, Tomoki Itou, Ryosuke Yamamura, Hirokazu Tanaka, Hirohiko Shibayama, Yutaka Shimazu, Hitoji Uchiyama, Satoshi Yoshihara, Yoko Adachi, Mitsuhiro Matsuda, Hitoshi Hanamoto, Nobuhiko Uoshima, Satoru Kosugi, Kensuke Ohta, Hideo Yagi, Yuzuru Kanakura, Itaru Matsumura, Masayuki Hino, Shosaku Nomura, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: Little is known about the real-world survival benefits and safety profiles of carfilzomib–lenalidomide–dexamethasone (KRd) and carfilzomib–dexamethasone (Kd). Methods: We performed a retrospective analysis to evaluate their efficacy
Externí odkaz:
https://doaj.org/article/c8a169335f1a487791719eaf9c1c6082
Autor:
Yuka Kawaji‐Kanayama, Tsutomu Kobayashi, Ayako Muramatsu, Hitoji Uchiyama, Nana Sasaki, Nobuhiko Uoshima, Mitsushige Nakao, Ryoichi Takahashi, Kazuho Shimura, Hiroto Kaneko, Miki Kiyota, Katsuya Wada, Yoshiaki Chinen, Koichi Hirakawa, Shin‐ichi Fuchida, Chihiro Shimazaki, Yayoi Matsumura‐Kimoto, Shinsuke Mizutani, Taku Tsukamoto, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background Combinatory strategies with carfilzomib (CFZ), a second‐generation proteasome inhibitor, plus dexamethasone (DEX) with or without lenalidomide (LEN) have shown promising efficacy for patients with relapsed/refractory multiple my
Externí odkaz:
https://doaj.org/article/bdff3f7ce0164c809dccfaff7fdd38f3
Autor:
Aya Nakaya, Hideo Yagi, Hitomi Kaneko, Satoru Kosugi, Toru Kida, Yoko Adachi, Hirohiko Shibayama, Takae Kohara, Yuri Kamitsuji, Shin-ichi Fuchida, Nobuhiko Uoshima, Eri Kawata, Hitoji Uchiyama, Yuji Shimura, Takayuki Takahashi, Fumiaki Urase, Kensuke Ohta, Tsuneyoshi Hamada, Kazue Miyamoto, Masayuki Kobayashi, Maki Shindo, Hirokazu Tanaka, Chihiro Shimazaki, Masayuki Hino, Junya Kuroda, Yuzuru Kanakura, Akifumi Takaoari-Kondo, Shosaku Nomura, Itaru Matsumura
Publikováno v:
Leukemia Research Reports, Vol 10, Iss , Pp 7-10 (2018)
We retrospectively analyzed twenty-six patients with primary plasma cell leukemia (pPCL) registered from May 2005 until April 2015 by the Kansai Myeloma Forum. Twenty patients received novel agents (bortezomib or lenalidomide), and their median survi
Externí odkaz:
https://doaj.org/article/60725e003e734cd185128c760bbe013a
Autor:
Kazutaka Sunami, Shin‐ichi Fuchida, Kenshi Suzuki, Masaki Ri, Morio Matsumoto, Chihiro Shimazaki, Hideki Asaoku, Hirohiko Shibayama, Kenichi Ishizawa, Hiroyuki Takamatsu, Takashi Ikeda, Dai Maruyama, Kazunori Imada, Michihiro Uchiyama, Toru Kiguchi, Satoshi Iyama, Hirokazu Murakami, Reiko Onishi, Keisuke Tada, Shinsuke Iida
Publikováno v:
Hematological oncologyREFERENCES.
The primary analysis of the phase 1/2 ISLANDs study in Japanese individuals with relapsed/refractory multiple myeloma (RRMM) showed that isatuximab monotherapy was well tolerated and effective, even in participants with high-risk cytogenetic abnormal
Autor:
Haruya Okamoto, Yu Inoue, Akihiro Miyashita, Yuka Kawaji-Kanayama, Shotaro Chinen, Takahiro Fujino, Taku Tsukamoto, Yuji Shimura, Shinsuke Mizutani, Hiroto Kaneko, Saeko Kuwahara, Shin-ichi Fuchida, Daichi Nishiyama, Koichi Hirakawa, Junya Kuroda
Publikováno v:
Blood. 140:12321-12322